73 related articles for article (PubMed ID: 17071630)
41. Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Engel C; Versmold B; Wappenschmidt B; Simard J; Easton DF; Peock S; Cook M; Oliver C; Frost D; Mayes R; Evans DG; Eeles R; Paterson J; Brewer C; ; McGuffog L; Antoniou AC; Stoppa-Lyonnet D; Sinilnikova OM; Barjhoux L; Frenay M; Michel C; Leroux D; Dreyfus H; Toulas C; Gladieff L; Uhrhammer N; Bignon YJ; Meindl A; Arnold N; Varon-Mateeva R; Niederacher D; Preisler-Adams S; Kast K; Deissler H; Sutter C; Gadzicki D; Chenevix-Trench G; Spurdle AB; Chen X; Beesley J; ; Olsson H; Kristoffersson U; Ehrencrona H; Liljegren A; ; van der Luijt RB; van Os TA; van Leeuwen FE; ; Domchek SM; Rebbeck TR; Nathanson KL; Osorio A; Ramón y Cajal T; Konstantopoulou I; Benítez J; Friedman E; Kaufman B; Laitman Y; Mai PL; Greene MH; Nevanlinna H; Aittomäki K; Szabo CI; Caldes T; Couch FJ; Andrulis IL; Godwin AK; Hamann U; Schmutzler RK;
Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2859-68. PubMed ID: 20978178
[TBL] [Abstract][Full Text] [Related]
42. CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies.
Yin M; Yan J; Wei S; Wei Q
Carcinogenesis; 2010 May; 31(5):850-7. PubMed ID: 20176653
[TBL] [Abstract][Full Text] [Related]
43. The six-nucleotide deletion/insertion variant in the CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck.
Li C; Lu J; Liu Z; Wang LE; Zhao H; El-Naggar AK; Sturgis EM; Wei Q
Cancer Prev Res (Phila); 2010 Feb; 3(2):246-53. PubMed ID: 20086182
[TBL] [Abstract][Full Text] [Related]
44. Identification of non-Hodgkin's lymphoma prognosis signatures using the CTGDR method.
Ma S; Zhang Y; Huang J; Han X; Holford T; Lan Q; Rothman N; Boyle P; Zheng T
Bioinformatics; 2010 Jan; 26(1):15-21. PubMed ID: 19850755
[TBL] [Abstract][Full Text] [Related]
45. Polymorphisms and haplotypes in the caspase-3, caspase-7, and caspase-8 genes and risk for endometrial cancer: a population-based, case-control study in a Chinese population.
Xu HL; Xu WH; Cai Q; Feng M; Long J; Zheng W; Xiang YB; Shu XO
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2114-22. PubMed ID: 19531679
[TBL] [Abstract][Full Text] [Related]
46. Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies.
Lan Q; Morton LM; Armstrong B; Hartge P; Menashe I; Zheng T; Purdue MP; Cerhan JR; Zhang Y; Grulich A; Cozen W; Yeager M; Holford TR; Vajdic CM; Davis S; Leaderer B; Kricker A; Schenk M; Zahm SH; Chatterjee N; Chanock SJ; Rothman N; Wang SS
Blood; 2009 Jul; 114(2):264-7. PubMed ID: 19414860
[TBL] [Abstract][Full Text] [Related]
47. Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk.
Hosgood HD; Baris D; Zhang Y; Berndt SI; Menashe I; Morton LM; Lee KM; Yeager M; Zahm SH; Chanock S; Zheng T; Lan Q
Leuk Res; 2009 Dec; 33(12):1609-14. PubMed ID: 19362737
[TBL] [Abstract][Full Text] [Related]
48. CASP3 polymorphisms and risk of squamous cell carcinoma of the head and neck.
Chen K; Zhao H; Hu Z; Wang LE; Zhang W; Sturgis EM; Wei Q
Clin Cancer Res; 2008 Oct; 14(19):6343-9. PubMed ID: 18829519
[TBL] [Abstract][Full Text] [Related]
49. Genetic susceptibility to lymphoma.
Skibola CF; Curry JD; Nieters A
Haematologica; 2007 Jul; 92(7):960-9. PubMed ID: 17606447
[TBL] [Abstract][Full Text] [Related]
50. HuGE systematic review and meta-analysis demonstrate association of CASP-3 and CASP-7 genetic polymorphisms with cancer risk.
Yan S; Li YZ; Zhu XW; Liu CL; Wang P; Liu YL
Genet Mol Res; 2013 May; 12(2):1561-73. PubMed ID: 23765963
[TBL] [Abstract][Full Text] [Related]
51. Role of CASP-10 gene polymorphisms in cancer susceptibility: a HuGE review and meta-analysis.
Yan S; Li YZ; Zhu JW; Liu CL; Wang P; Liu YL
Genet Mol Res; 2012 Nov; 11(4):3998-4007. PubMed ID: 23212337
[TBL] [Abstract][Full Text] [Related]
52. Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma.
Lan Q; Zheng T; Chanock S; Zhang Y; Shen M; Wang SS; Berndt SI; Zahm SH; Holford TR; Leaderer B; Yeager M; Welch R; Hosgood D; Boyle P; Rothman N
Carcinogenesis; 2007 Apr; 28(4):823-7. PubMed ID: 17071630
[TBL] [Abstract][Full Text] [Related]
53. Caspase polymorphisms and genetic susceptibility to multiple myeloma.
Hosgood HD; Baris D; Zhang Y; Zhu Y; Zheng T; Yeager M; Welch R; Zahm S; Chanock S; Rothman N; Lan Q
Hematol Oncol; 2008 Sep; 26(3):148-51. PubMed ID: 18381704
[TBL] [Abstract][Full Text] [Related]
54. The Effect of Caspase 8, 9 Gene Polymorphisms on Non-Hodgkin Lymphoma Susceptibility and Clinical/Pathological Features.
Barati F; Bahari G; Asadi A; Nakhaee A; Hashemi SM; Taheri M; Hashemi M
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4339-4346. PubMed ID: 36580018
[TBL] [Abstract][Full Text] [Related]
55. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma.
Li C; Zhao H; Hu Z; Liu Z; Wang LE; Gershenwald JE; Prieto VG; Lee JE; Duvic M; Grimm EA; Wei Q
Hum Mutat; 2008 Dec; 29(12):1443-51. PubMed ID: 18563783
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
